@JAMA_current
Account based inUnited States
About this account
- Account based in
- United States
- Connected via
- United States App Store
Account-level information from X, not a live location or the device used for a specific post.
JAMA is an international peer-reviewed general medical journal published weekly online and in print, and a member of the @JAMANetwork family of journals.
Chicago, IL
Joined May 2009
- Tweets51.4K
- Following440
- Followers495K
- Likes2.1K
馃У Presented at #ANES26: Among high-risk patients undergoing elective major abdominal surgery, individualized #CardiacIndex-guided hemodynamic therapy targeting each patient鈥檚 preoperative resting cardiac index did not reduce a composite of acute kidney injury, acute myocardial injury, severe infectious complications, nonfatal cardiac arrest, or death within 7 postoperative days vs routine hemodynamic therapy.
These findings do not support this strategy for routine intraoperative management in this surgical population.
ja.ma/4isLQ91
@ASALifeline
馃搳 Research Summary: In high-risk elective major abdominal surgery, individualized #HemodynamicTherapy maintained intraoperative cardiac index closer to preoperative resting values but did not improve the primary postoperative outcome vs routine care.
ja.ma/4i5eziJ
#ANES26 @ASALifeline
馃敄 This trial is featured in @JAMAplusTrials, a platform that highlights the implications and innovations of #ClinicalTrial research from across the JAMA Network to advance evidence-based #medicine and public #health.
This October's Trial Theme of the Month focuses on extension studies in #ClinicalTrials, where long-term findings depend on how comparison groups are defined and how attrition and selection bias are handled. Read the latest editorial: ja.ma/4j8Jop4
馃摤 Learn more and subscribe to the email newsletter: ja.ma/4jOy4yD
馃挰 Viewpoint by Gayatri Devi, MD, MS: Blood-based biomarkers for #AlzheimerDisease may help diagnose symptomatic patients, but their role in asymptomatic adults remains uncertain.
In people without symptoms, positive test results may have limited predictive value for future cognitive decline and may introduce psychological, financial, insurance, and employment consequences without established preventive benefit.
ja.ma/3VSNpEy
Under the Increasing Organ Transplant Access model by the Centers for Medicare & Medicaid Services (CMS), most participating #KidneyTransplant centers publicly posted waitlist selection criteria, but about 1 in 3 did not.
Among centers that posted criteria, most materials exceeded recommended reading levels and were rarely available in non-English languages, indicating that policy compliance did not consistently translate into functional transparency for patients.
ja.ma/4ypgGnJ
馃搳 JAMA Clinical Guidelines Synopsis: The 2025 @IDSAInfo guideline for adults with c omplicated #UrinaryTractInfection recommends selecting empirical antibiotic therapy based on severity of illness, risk factors for resistance, patient-specific considerations, and recent local antibiogram data.
For patients who are clinically improving, the guidance supports shorter treatment courses and transition from intravenous to oral antibiotics when an effective oral option is available.
ja.ma/4yW7bxl
Among individuals of African ancestry, a common #CD36 nonsense variant was associated with higher risk of dilated #cardiomyopathy in a dose-dependent pattern, with homozygous carriers having approximately 5-fold higher risk.
In 4 US cohorts, this variant accounted for more of the dilated cardiomyopathy burden than #TTN truncating variants, indicating that current genetic frameworks may miss a major contributor in this population.
ja.ma/3Wy9k40
馃摚 Interested in publishing in @JAMA_AI_?
From generative and agentic #AI to #clinical decision support, AI-enabled diagnostic and therapeutics to digital health technologies and the methods needed to evaluate their safety, effectiveness, and impact, JAMA AI will publish research spanning the full spectrum of computational #health.
Beginning in early 2027, the journal will welcome submissions.
鉁夛笍 Sign up for updates and future announcements: ja.ma/4sad9rQ
"The opportunities created by AI are extraordinary, but realizing their potential requires rigorous evaluation."
In this announcement, Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of JAMA and the JAMA Network, discusses how @JAMA_AI_ will provide a trusted forum for research, education, and debate on the technologies shaping clinical practice.
馃摪 Read the press release: ja.ma/4zG00JB
鉃★笍 Learn more and sign up for updates: ja.ma/4dKCIdc
What does it take to lead a successful clinical trial?
This week in Tanzania, Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of JAMA and the JAMA Network, and JAMA Associate Editor Michael Lipnick, MD, will teach The Fine Art of Clinical Trials, a long-running international course focused on the skills required to design, lead, and sustain impactful clinical research.
Held in Africa for the first time, the course aims to support researchers in developing expertise in trial leadership, strategy, governance, funding, and conducting studies in settings with limited resources while expanding regional and global research collaborations.
鉃★笍 Learn more: ja.ma/4ynVkas
馃摉 Explore global health research, commentary, and evidence from the JAMA Network: ja.ma/47UCv3M
The Fine Art of Clinical Trials course is coordinated by
@anzicrc at Monash University in partnership with the African Acute Care Trials Network (AACUTNet), bringing together faculty from Africa, Australia, and the broader global clinical research community.
Drs Bibbins-Domingo and Lipnick are among the international faculty contributing to this effort to strengthen clinical trial leadership and expand opportunities for Africa-led participation in global research.
In this editorial, Roy H. Perlis, MD, MSc, Annette Flanagin, RN, MA, and Kirsten Bibbins-Domingo, PhD, MD, MAS discuss the launch of @JAMA_AI_, a new JAMA Network journal dedicated to publishing rigorous, clinically focused research spanning AI, digital health, and computational health.
馃摉 Read the Editorial: ja.ma/4zaWnMh
#MedNews: The US primary care shortage is deepening, leaving millions without timely access to care. What will it take to rebuild the workforce?
New training pathways, expanded opportunities for international medical graduates, and payment reform may all play a role.
Learn more: ja.ma/4zF4dxq
#MedNews: Reducing lipoprotein(a) levels was widely assumed to be the next big breakthrough in cardiovascular disease, and European and US clinical guidelines already recommend measuring Lp(a) in all adults.
But after the Lp(a)-lowering agent pelacarsen failed to prevent major adverse cardiovascular events in a phase 3 trial, many are wondering what comes next.
ja.ma/4eDQQoX
Among patients with #SepticShock undergoing surgical source control, intraoperative dobutamine plus norepinephrine reduced new-onset or worsening #AcuteKidneyInjury within 7 days after surgery compared with norepinephrine alone. These findings support consideration of this intraoperative hemodynamic strategy for reducing postoperative kidney injury in this surgical population.
ja.ma/4i3tEBq
馃敄 This trial is featured in @JAMAplusTrials, a platform that highlights the implications and innovations of #ClinicalTrial research from across the JAMA Network to advance evidence-based #medicine and public #health.
This October's Trial Theme of the Month focuses on extension studies in #ClinicalTrials, where long-term findings depend on how comparison groups are defined and how attrition and selection bias are handled. Read the latest editorial: ja.ma/4j8Jop4
馃摣 Learn more and subscribe to the email newsletter: ja.ma/4jOy4yD
馃帶 What role should AI play in the future of medicine?
In the latest JAMA+ AI Conversations podcast, inaugural Editor in Chief Roy H. Perlis, MD, MSc discusses the vision for @JAMA_AI_, the evolving landscape of #AI in health care, and why rigorous evaluation remains essential as these technologies move into clinical practice.
鈻讹笍 Listen now: ja.ma/4ytBgnd
馃敆 Explore JAMA AI: ja.ma/4hZYLxX
馃挕 JAMA Insights: In the US, #Autopsy remains important for #PublicHealth surveillance, cause-of-death determination, and identification of diagnostic errors, treatment complications, and emerging disease patterns.
Yet fewer than 8% of deaths undergo autopsy, and consented hospital autopsy rates have declined substantially over the past 60 years.
ja.ma/4dDKRjF
馃搫 JAMA Patient Page: An #Autopsy is a medical examination performed by pathologists that can help identify an individual鈥檚 cause of death.
This JAMA Patient Page explains the 2 main types of autopsy in the US, how often autopsies are performed, and how they can identify unsuspected diagnoses, complications of disease or treatment, and findings relevant to family members and #PublicHealth.
ja.ma/4yzsTGM
In mechanically ventilated adults with #AcuteHypoxemicRespiratoryFailure, an inhaled sedation strategy using isoflurane with intravenous adjuncts as needed did not reduce hospital mortality vs intravenous sedation. Ventilator-free days, intensive care unit鈥揻ree days, hospital-free days, and 3-month quality-of-life and disability scores were also similar between groups.
ja.ma/3TKDpfY
馃敄 This trial is featured in @JAMAplusTrials, a platform that highlights the implications and innovations of #ClinicalTrial research from across the JAMA Network to advance evidence-based #medicine and public #health.
This October's Trial Theme of the Month focuses on extension studies in #ClinicalTrials, where long-term findings depend on how comparison groups are defined and how attrition and selection bias are handled. Read the latest editorial: ja.ma/4j8Jop4
馃摤 Learn more and subscribe to the email newsletter: ja.ma/4jOy4yD